SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Cabirta A)
 

Sökning: WFRF:(Cabirta A) > Simultaneous Onset ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004828naa a2201153 4500
001oai:prod.swepub.kib.ki.se:151274975
003SwePub
008240701s2022 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1512749752 URI
024a https://doi.org/10.3390/cancers142255302 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Cattaneo, C4 aut
2451 0a Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
264 c 2022-11-10
264 1b MDPI AG,c 2022
520 a Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
700a Salmanton-Garcia, J4 aut
700a Marchesi, F4 aut
700a El-Ashwah, S4 aut
700a Itri, F4 aut
700a Weinbergerova, B4 aut
700a Da Silva, MG4 aut
700a Dargenio, M4 aut
700a Davila-Valls, J4 aut
700a Martin-Perez, S4 aut
700a Farina, F4 aut
700a Van Doesum, J4 aut
700a Valkovic, T4 aut
700a Besson, C4 aut
700a Poulsen, CB4 aut
700a Lopez-Garcia, A4 aut
700a Zak, P4 aut
700a Schonlein, M4 aut
700a Piukovics, K4 aut
700a Jaksic, O4 aut
700a Cabirta, A4 aut
700a Ali, N4 aut
700a Sili, U4 aut
700a Fracchiolla, N4 aut
700a Dragonetti, G4 aut
700a Adzic-Vukicevic, T4 aut
700a Marchetti, M4 aut
700a Machado, M4 aut
700a Glenthoj, A4 aut
700a Finizio, O4 aut
700a Demirkan, F4 aut
700a Blennow, Ou Karolinska Institutet4 aut
700a Tisi, MC4 aut
700a Omrani, AS4 aut
700a Navratil, M4 aut
700a Racil, Z4 aut
700a Novak, J4 aut
700a Magliano, G4 aut
700a Jimenez, M4 aut
700a Garcia-Vidal, C4 aut
700a Erben, N4 aut
700a Del Principe, MI4 aut
700a Buquicchio, C4 aut
700a Bergantim, R4 aut
700a Batinic, J4 aut
700a Al-Khabori, M4 aut
700a Verga, L4 aut
700a Szotkowski, T4 aut
700a Samarkos, M4 aut
700a Ormazabal-Velez, I4 aut
700a Meers, S4 aut
700a Maertens, J4 aut
700a Pinczes, LI4 aut
700a Hoenigl, M4 aut
700a Drgona, L4 aut
700a Cuccaro, A4 aut
700a Bilgin, YM4 aut
700a Aujayeb, A4 aut
700a Rahimli, L4 aut
700a Grafe, S4 aut
700a Sciume, M4 aut
700a Mladenovic, M4 aut
700a Colak, GM4 aut
700a Sacchi, MV4 aut
700a Nordlander, Au Karolinska Institutet4 aut
700a Venemyr, CB4 aut
700a Hanakova, M4 aut
700a Garcia-Pouton, N4 aut
700a Emarah, Z4 aut
700a Zambrotta, GPM4 aut
700a Rodrigues, RN4 aut
700a Cordoba, R4 aut
700a Mendez, GA4 aut
700a Biernat, MM4 aut
700a Cornely, OA4 aut
700a Pagano, L4 aut
710a Karolinska Institutet4 org
773t Cancersd : MDPI AGg 14:22q 14:22x 2072-6694
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:151274975
8564 8u https://doi.org/10.3390/cancers14225530

Hitta via bibliotek

  • Cancers (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy